SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 28, 2005
CuraGen Corporation
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 0-23223 | | 06-1331400 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
322 East Main Street
Branford, Connecticut 06405
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (203) 481-1104
555 Long Wharf Drive, 11th Floor
New Haven, Connecticut 06511
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01.Regulation FD Disclosure.
On September 28, 2005, CuraGen Corporation announced that it expects to complete, this week, the enrollment of patients in its Phase II randomized, double-blind, placebo-controlled clinical trial evaluating a single-dose of velafermin (CG53135) for the prevention of oral mucositis (OM) in cancer patients undergoing bone marrow transplantation (BMT). To date, more than 200 patients have been treated with velafermin in this trial, and the last patient is expected to be enrolled by the end of September.
A copy of the press release is attached to this Current Report on Form 8-K asExhibit 99.1, and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) The following exhibit is furnished with this report:
| | |
Exhibit
Number
| | Description
|
| 99.1 | | Press release of Registrant dated September 28, 2005. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | | CURAGEN CORPORATION |
| | | (Registrant) |
| | |
| Date: September 29, 2005 | | By: | | /s/ Elizabeth A. Whayland
|
| | | Name: | | Elizabeth A. Whayland |
| | | Title: | | Vice President of Finance and |
| | | | | Corporate Secretary |
